Zobrazeno 1 - 10
of 108
pro vyhledávání: '"B. Billemont"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
B. Billemont, Eric Van Cutsem, David Khayat, Karen Soussan-Lazard, Sylvaine Cartot-Cotton, Olivier Rixe, Sabine Tejpar, Jean-Baptiste Meric, Sylvie Assadourian, Chris Verslype
Publikováno v:
European Journal of Cancer. 49:17-24
Background To determine dose-limiting toxicities (DLTs), recommended phase II trial dose (RPTD), safety, preliminary antitumour activity and pharmacokinetics of intravenous aflibercept with irinotecan, 5-fluorouracil and leucovorin (LV5FU2). Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cccb4579bc4928495637f5adc42f5906
https://doi.org/10.1016/j.ejca.2012.07.007
https://doi.org/10.1016/j.ejca.2012.07.007
Publikováno v:
Bulletin du Cancer. 97:S53-S63
New medical strategies have emerged over the past decade for the treatment of advanced renal cell carcinoma based on the discovery of specific molecular abnormalities. However, molecular targeted therapeutics including anti-angiogenics have demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4556b6c07b8f712c4d00de4dcc238af
https://doi.org/10.1684/bdc.2010.1070
https://doi.org/10.1684/bdc.2010.1070
Publikováno v:
Cancer Research. 78:P6-03
Patients (pts) with HER2-positive breast cancer (BC) have a high risk of developing brain metastases (BM) that might be due to longer survival, low diffusion of Trastuzumab (T) in the CNS or an unknown incidence of occult BM at diagnosis. In a series
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67ed0a3cc5a33186d86ba528413beec0
https://doi.org/10.1158/1538-7445.sabcs17-p6-03-06
https://doi.org/10.1158/1538-7445.sabcs17-p6-03-06
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Targeted Oncology. 4:121-133
The use of molecular targeted therapies for the treatment of cancer has increased over the last decade. The benefits of these compounds in terms of efficacy are often relatively modest and counter balanced by the occurrence of significant toxicities.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceb8944f093e0df1f54a65bc3374370b
https://doi.org/10.1007/s11523-009-0109-x
https://doi.org/10.1007/s11523-009-0109-x
Autor:
Olivier Rixe, Laurent Taillade, Valentine Sultan-Amar, B. Billemont, Jean-Baptiste Meric, I. Alexandre
Publikováno v:
Bulletin du Cancer. 96:045-055
Angiogenesis or new blood vessel formation is a complex and fundamental event in the process of tumor growth and metastatic dissemination. Actually, most of antiangiogenic agents target the VEGF considered like the most potent proangiogenic factor. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79ac934a7c30ea8fa732fb5da873c990
https://doi.org/10.1684/bdc.2008.0775
https://doi.org/10.1684/bdc.2008.0775
Publikováno v:
Annals of Oncology. 18:ix83-ix86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104b97da9a1a0dc45ade8156db0791e8
https://doi.org/10.1093/annonc/mdm298
https://doi.org/10.1093/annonc/mdm298
Autor:
Corinne Isnard-Bagnis, Samir Saeb, Nadine Casimir, Olivier Rixe, Edward Bourry, B. Billemont, Svetlana Karie, Lucille Mercadal, Vincent Launay-Vacher, Hassane Izzedine, Isabelle Tostivint, Isabelle Brocheriou, Gilbert Deray
Publikováno v:
Nephrology Dialysis Transplantation. 21:3038-3045
Thrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterized by predominantly platelet thrombi in the renal and/or systemic circulations. Haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4b1cdabbcd9074f801fa201708a4b2f
https://doi.org/10.1093/ndt/gfl507
https://doi.org/10.1093/ndt/gfl507
Autor:
Hassane Izzedine, Marc-Olivier Bitker, V. Sultan, O. Rixe, Frederic Thibault, B. Billemont, S. Bart
Publikováno v:
Progrès en Urologie. 18:480-482
Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity. Up to now, no medical treatment has allowed regression of vena cava tumour thrombus. The authors report the case of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b91c67acfc21726f6a6437ad4ee50998
https://doi.org/10.1016/j.purol.2008.04.018
https://doi.org/10.1016/j.purol.2008.04.018